These findings provide insights into the mechanisms that underlie Dyrk1b-induced hepatic lipogenesis and hepatic insulin resistance and identify Dyrk1b as a therapeutic target for NASH and insulin resistance in the liver. The gene discussed is INS; the disease is metabolic dysfunction-associated steatohepatitis.